Systemic Lupus Erythematosus (SLE) is chronic autoimmune disorder. It is characterized by excess production of the antibodies that attacks body’s own cells and vital organs. Various symptoms associated with the disease includes joint pain, swelling, rashes over face (butterfly rash) and other body area, severe fatigue, hair loss, anemia, and Raynaud’s phenomenon etc. SLE can also affect vital body organs such as heart, kidney, lungs, and behavioral changes. Exact causes of the disease is unknown, however, hereditary and environmental factors could be lead to SLE. There is no direct cure available for SLE, however, symptomatic treatment can be administered to lower or eliminate symptoms associated with disease. Major classes of drugs commonly used are antimalarial agents such as chlorquine and hydrochlorquine; topical steroid cream for rashes; NSAIDS for joint pain; and fever steroidal medication such as glucocorticoids through IV or oral route and immunosuppressive agents to lower immune response from the antibodies.
Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1540
Rise in incidence of SLE is one of major factors driving growth of the systemic lupus erythematosus treatment market. According to study published in the Expert Review of Clinical Immunology in 2017, the global incidence rate varied from about 0.3–23.7 per 100,000 person and the prevalence rates varied in the range from 6.5 to 178.0 per 100,000 people. Key companies are entering into collaborations for research and development in systemic lupus erythematosus, which is expected to support growth of the market. For instance, in 2015, a genomic mapping company, 23andMe, Inc. collaborated with Pfizer, Inc. to study and understand the genetics of lupus thereby, to develop treatment for it. In 2012, Alliance for Lupus Research and Pfizer’s Centers for Therapeutic Innovation collaborated to discover new therapies for patients living with systemic lupus erythematosus. Increasing approvals for products for the treatment of SLE is another factor expected to aid in growth of the market.
For instance, GlaxoSmithKline, in July 2017, received U.S.FDA approval for the subcutaneous form of its biologic drug belimumab for treatment of systemic lupus erythematosus. Clinical guidelines to include biologics in the treatment of systemic lupus erythematosus would further aid in market growth. Multidisciplinary group consisting international experts in various branches such as internal medicine, rheumatology, nephrology, dermatology, pediatrics, and cardiology published recommendations in journal Autoimmune Review in 2017, for the use of biologics in patients with systemic lupus erythematosus, according to which biologic drugs such as abatacept, rituximab, or tocilizumab can be used after evaluating patient profile.
North America is expected to be the dominant market in the global SLE treatment market, over the forecast period. This is owing to relatively higher prevalence of SLE in this region as compared to other regions. According to study published in the Rheumatology Journal, in May 2017, incidence and prevalence of SLE in North America was 23.2 people per 1, 00,000 and 241 per 1, 00,000 people, respectively. High presence of market players in North America is also another factor for growth of the market in this region. Key players such as GlaxoSmithKline, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb in systemic lupus erythematosus market have high presence in this region.
Key players operating in the systemic lupus erythematosus treatment market are GlaxoSmithKline Plc (GSK), F. Hoffmann-La Roche Ltd, Anthera Pharmaceuticals Inc., Bristol-Myers Squibb, Eli Lilly, Pfizer Limited, Merck KGaA, Immupharma Plc, Sanofi, Lycera Corporation, Aurinia Pharmaceuticals Inc., Mylan N.V., and Sandoz International GmbH.